New immune therapy combo aims to tame chronic GVHD in Steroid-Resistant patients
NCT ID NCT01937468
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-phase trial tests the safety of combining donor anti-inflammatory Treg cells with low-dose Interleukin-2 (IL-2) for people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a complication after a stem cell or bone marrow transplant where the donor's immune cells attack the recipient's body. The study enrolls 25 participants and aims to find the safest dose of this combination, which may help control the immune attack without the need for high-dose steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Regulatory T-cells (Treg) and low-dose Interleukin-2 (IL-2)
What this could lead to
If this works, it could point toward a new way to control chronic GVHD without high-dose steroids, helping patients who have not responded to standard treatment.
What could go wrong
This is a very early phase I trial with only 25 participants, focused on safety and dosing. It may not show clear benefit, and there are risks from the cell infusion and IL-2, including immune reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.